Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06694558 · ClinicalTrials.gov registry record

Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease

A clinical trial of Type 1 Diabetes (T1D) and Chronic Kidney Disease (CKD), sponsored by The Cleveland Clinic.

Recruiting
Registry status
60
Enrollment target
1
Study location

NCT06694558: Recruiting study of Type 1 Diabetes (T1D) and Chronic Kidney Disease (CKD), sponsored by The Cleveland Clinic.

NCT06694558 is a study of Type 1 Diabetes (T1D) and Chronic Kidney Disease (CKD) that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 60 participants, below the 177-participant average among 17 other Type 1 Diabetes (T1D) trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06694558, a study of Type 1 Diabetes (T1D) and Chronic Kidney Disease (CKD), is actively recruiting participants, sponsored by The Cleveland Clinic.

RECRUITING
Registry status
60 participants
Enrollment target
1
Study location

Study Summary

This is a cross-sectional study in patients with Type 1 diabetes (TID) and chronic kidney disease (CKD) to test if time in range (TIR) affects the degree of hyperglycemia required for monocyte activation, podocyte injury, and assess if monocyte activation is attenuated by glucagon-like peptide (GLP-1) agonist treatment ex vivo.

Primary Outcome

Number of subjects with proinflammatory monocytes by flow cytometry, higher ER stress, and cytokine levels after monocyte exposure to hyperglycemia compared to euglycemia for 6 hours

Conditions Studied

Type 1 Diabetes (T1D) Chronic Kidney Disease (CKD)

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-03-01
Est. Completion 2026-07-01
The Cleveland Clinic

688 total trials

What NCT06694558 shows while recruiting

NCT06694558 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 177-participant average among 17 other Type 1 Diabetes (T1D) trials with a reported enrollment target (66% lower).

The record links to 2 conditions, with Type 1 Diabetes (T1D) appearing as the primary indexed condition, and to 0 interventions.

NCT06694558 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT06694558 about?

NCT06694558 is a clinical study titled "Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease". This is a cross-sectional study in patients with Type 1 diabetes (TID) and chronic kidney disease (CKD) to test if time in range (TIR) affects the degree of hyperglycemia required for monocyte activation, podocyte injury, and assess if monocyte activation is attenuated by glucagon-like peptide (GLP-...

What is the current status of trial NCT06694558?

This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2025-03-01. Estimated completion is 2026-07-01.

What conditions does trial NCT06694558 study?

This clinical trial studies the following conditions: Type 1 Diabetes (T1D), Chronic Kidney Disease (CKD).

Who is sponsoring clinical trial NCT06694558?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06694558 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes (T1D)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06694558's enrollment target sits among peer trials

60 7th of 17 higher than 10 of 17 other Type 1 Diabetes (T1D) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes (T1D) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06694558

Source: ClinicalTrials.gov NCT06694558, the US trial registry maintained by the National Library of Medicine. NCT06694558 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.